RxDoctor Payments Data

Steve Hamberis, MD

Family Medicine · Greenville, SCNPI 1891739439

Payments from drug & device makers

$18,902in general payments, 2019–2025

Across 1,309 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • Amgen$819
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$18,877100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)230$2,424
Novo Nordisk210$2,338
Lilly USA, LLC170$1,519
AstraZeneca46$1,234
Pfizer94$1,124
Amgen(2 entities)49$819
Takeda Pharmaceuticals U.S.A., Inc.45$740
Otsuka America Pharmaceutical, Inc.34$626
Johnson & Johnson32$605
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC30$562
Exact Sciences18$525
Biohaven Pharmaceuticals, Inc.13$495
Esperion Therapeutics, Inc.24$432
GSK24$415
Amarin Pharma, Inc.25$396
Sanofi-aventis U.S. LLC16$351
Novartis20$327
Abbott15$310
Axsome Therapeutics, Inc.15$306
Antares Pharma, Inc.17$289
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$253
Daiichi Sankyo Inc.11$204
Corium, LLC14$195
Paratek Pharmaceuticals, Inc.6$187
Dexcom, Inc.11$175
Eisai Inc.9$161
Lundbeck LLC9$155
Boehringer Ingelheim9$128
Sumitomo Pharma America, Inc.6$127
Biohaven Pharmaceutical Holding Company Ltd.13$127
Astellas Pharma US Inc8$119
Nestle Healthcare Nutrition Inc.8$117
Merck5$80
Hikma Pharmaceuticals USA5$77
Idorsia Pharmaceuticals US Inc5$72
Adlon Therapeutics L.p.4$61
Phathom Pharmaceuticals, Inc.4$59
Bayer4$58
Supernus Pharmaceuticals, Inc.3$56
E.r. Squibb & Sons, L.L.C.4$54
Amneal Pharmaceuticals LLC4$51
Tris Pharma Inc2$50
Edwards Lifesciences2$49
Upsher-smith Laboratories LLC3$48
Halozyme Inc2$42
Arbor Pharmaceuticals, Inc.3$42
Sunovion Pharmaceuticals Inc.2$38
Mannkind Corporation2$35
Eyevance Pharmaceuticals LLC1$24
Genentech USA, Inc.2$23
Scilex Pharmaceuticals Inc.1$21
Phadia US Inc.1$20
Impel Pharmaceuticals Inc.1$19
Vanda Pharmaceuticals Inc.1$17
Bausch Health US, LLC1$16
UCB, Inc.1$15
Dynavax Technologies Corporation1$15
Therapeuticsmd, Inc.1$14
Currax Pharmaceuticals LLC1$13
Neos Therapeutics, LP1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,902 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$391,037
Medicare patients
502
Services billed
22,576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide198$291,497
MounjaroTirzepatide146$219,449
TrulicityDulaglutide107$168,890
EliquisApixaban144$150,140
VraylarCariprazine Hcl50$93,477
JardianceEmpagliflozin60$87,088
Tresiba Flextouch U-200Insulin Degludec96$78,560
XareltoRivaroxaban53$67,795
FarxigaDapagliflozin Propanediol57$64,211
EntrestoSacubitril/Valsartan48$54,940
LinzessLinaclotide43$49,373
MyrbetriqMirabegron48$38,749
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$28,839
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$28,470
Aimovig AutoinjectorErenumab-Aooe24$27,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,519$388,339253 claims
Novo NordiskOzempic$2,338$291,497198 claims
AbbVieVraylar, Linzess, Qulipta, Ubrelvy, Synthroid$2,424$181,118198 claims
PfizerEliquis, Premarin$1,124$156,355157 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,234$96,955110 claims
Boehringer IngelheimJardiance$128$87,08860 claims
Johnson & JohnsonXarelto$605$67,79553 claims
NovartisEntresto$327$54,94048 claims
GSKTrelegy Ellipta, Breo Ellipta$415$45,29865 claims
Astellas Pharma US IncMyrbetriq$119$38,74948 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$740$32,16142 claims
MerckBelsomra, Januvia$80$31,24939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →